This article is more than 5 years old. Information may no longer be current.

Bausch + Lomb, Tatvum Research enter IOL design licensing agreement

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Bausch + Lomb has entered into a licensing agreement with Tatvum Research for the worldwide commercial rights to new IOL designs that will be used in the enVista IOL family, according to a press release.

The advanced enVista IOLs, which will address astigmatism and presbyopia, were developed in partnership by the two companies.

“This agreement is part of our continued investment in expanding and improving upon our IOL options for our customers and their patients” Chuck Hess, vice president and general manager, U.S. Surgical, Bausch + Lomb, said in the release. “We look forward to applying these innovative designs on our rapidly growing enVista IOLs.”

Bausch + Lomb will file for regulatory approval of the IOLs in the coming years.